Elizabeth Bhatt
Direktor/Vorstandsmitglied bei EFFECTOR THERAPEUTICS, INC.
Vermögen: 653 $ am 30.04.2024
Aktive Positionen von Elizabeth Bhatt
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
EFFECTOR THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 25.08.2021 | - |
Independent Dir/Board Member | 25.08.2021 | - | |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Geschäftsführer | 28.07.2022 | - |
Karriereverlauf von Elizabeth Bhatt
Ehemalige bekannte Positionen von Elizabeth Bhatt
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ACHAOGEN | Geschäftsführer | 26.07.2018 | 30.06.2019 |
Corporate Officer/Principal | 18.09.2017 | 26.07.2018 | |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01.05.2011 | 01.09.2017 |
EFFECTOR THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.01.2021 | - |
Independent Dir/Board Member | 01.01.2021 | - | |
APPLIED MOLECULAR TRANSPORT INC. | Corporate Officer/Principal | 01.09.2019 | - |
Ausbildung von Elizabeth Bhatt
Pomona College | Undergraduate Degree |
Kellogg School of Management | Masters Business Admin |
University of California San Diego | Graduate Degree |
Statistik
International
Vereinigte Staaten | 10 |
Operativ
Corporate Officer/Principal | 3 |
Chief Operating Officer | 2 |
Director/Board Member | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 4 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
APPLIED MOLECULAR TRANSPORT INC. | Health Technology |
EFFECTOR THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Achaogen, Inc.
Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Locust Walk Acquisition Corp.
Locust Walk Acquisition Corp. Financial ConglomeratesFinance Locust Walk Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on October 2, 2020 and is headquartered in Boston, MA. | Finance |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Health Technology |
- Börse
- Insiders
- Elizabeth Bhatt
- Erfahrung